Travere Therapeutics CAO Sandra Calvin to retire Feb 2027; VP Controller John Torell to succeed

Filed July 9, 2026 · Period ending July 6, 2026 · ~1 min read

Key Changes

• medium

  Chief accounting officer Sandra Calvin will retire following the Feb 2027 10-K filing; VP Controller John Torell expected to succeed her as CAO and principal accounting officer.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• low

  Torell has overseen accounting operations, financial reporting, SEC reporting, and internal controls since joining in 2021; served as VP Controller since 2023.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →